Evidence map›Paper›PMID 35234161›Full record

ReviewJournal of musculoskeletal & neuronal interactions2022

The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Amish Chinoy, Grace R Vassallo, Emma Burkitt Wright, Judith Eelloo, Siobhan West, Eileen Hupton, Paula Galloway, Amy Pilkington, Raja Padidela, M Zulf Mughal

Open access · greenAbstract readReview
In one paragraph

Review in Journal of musculoskeletal & neuronal interactions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Amish ChinoyDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Grace R VassalloNHSE Highly Specialised Service for Complex NF1, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Emma Burkitt WrightFaculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
Judith EellooNHSE Highly Specialised Service for Complex NF1, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Siobhan WestNHSE Highly Specialised Service for Complex NF1, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Eileen HuptonNHSE Highly Specialised Service for Complex NF1, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Paula GallowayTherapy and Dietetic Department, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Amy PilkingtonTherapy and Dietetic Department, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Raja PadidelaDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
M Zulf MughalDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Manchester University NHS Foundation Trust · GBRoyal Manchester Children's Hospital · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) can affect multiple systems in the body. An under recognised phenotype is one of muscle weakness. Clinical studies using dynamometry and jumping mechanography have demonstrated that children with NF1 are more likely to have reduced muscle force and power. Many children with NF1 are unable to undertake physical activities to the same level as their peers, and report leg pains on physical activity and aching hands on writing. Children and adolescents with NF1 reporting symptoms of muscle weakness should have a focused assessment to exclude alternative causes of muscle weakness. Assessments of muscle strength and fine motor skills by physiotherapists and occupational therapists can provide objective evidence of muscle function and deficits, allowing supporting systems in education and at home to be implemented. In the absence of an evidence base for management of NF1-related muscle weakness, we recommend muscle-strengthening exercises and generic strategies for pain and fatigue management. Currently, trials are underway involving whole-body vibration therapy and carnitine supplementation as potential future management options.

Indexed as

Neurofibromatosis 1AdolescentHumansMuscle, SkeletalMuscle StrengthMuscle WeaknessPhenotypeFatigueMotor SkillsMuscleNF1Strength

Identifiers

PMID35234161
PMCPMC8919663
OpenAlexW4214954745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.